Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Brokerages

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given a consensus recommendation of "Buy" by the eight analysts that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $19.43.

A number of research firms have weighed in on REPL. BMO Capital Markets upped their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Jefferies Financial Group upped their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th.

Replimune Group Stock Performance

REPL stock traded up $0.10 on Monday, hitting $11.60. The company's stock had a trading volume of 413,597 shares, compared to its average volume of 701,107. The firm has a 50 day moving average of $12.66 and a two-hundred day moving average of $12.13. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The stock has a market cap of $893.37 million, a price-to-earnings ratio of -3.78 and a beta of 1.30. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Remove Ads

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Equities analysts predict that Replimune Group will post -2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Baker BROS. Advisors LP boosted its holdings in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after acquiring an additional 1,000,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after acquiring an additional 1,083,633 shares in the last quarter. Redmile Group LLC boosted its holdings in shares of Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after acquiring an additional 124,344 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Replimune Group by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company's stock valued at $43,546,000 after acquiring an additional 129,601 shares in the last quarter. Finally, Braidwell LP boosted its holdings in Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company's stock worth $33,656,000 after buying an additional 2,057,460 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.